Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen sees its Relative Strength Rating enter the 80-plus level.

Stocks To Watch: Amgen Sees Relative Strength Rating Jump To 83

An appeals court ruled in Amgen's (AMGN) favor in a case challenging the validity of two patents on its top-selling medicine, Enbrel.

Amgen Gets Favorable Appeals Court Ruling for Enbrel Patent

Amgen (AMGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Amgen (AMGN) Looks Good: Stock Adds 8.2% in Session

Despite a 27% rise since the March 23 lows of this year, at the current price of around $235 per share we believe Amgen Inc. stock has more room for growth.

Is There More Upside For Amgen At $235?

Netflix

The Nasdaq scored some more gains Wednesday.

Amgen's Win, Netflix's Hire Send Nasdaq Higher

Amgen (NASDAQ: AMGN) shares are trading higher on Wednesday after an appeals court confirmed the validity of its Enbrel patents.

Why Amgen's Stock Is Trading Higher Today

Investors reacted positively to a big patent litigation win for the biotech.

Why Amgen Shares Jumped Today

An appeals court ruling means biosimilar competition won't affect U.S. Enbrel sales for a long time.

Amgen's Enbrel Patents to Be Upheld Through 2029

Amgen stock popped Wednesday after an appeals court blocked Novartis from knocking off the biotech giant's blockbuster drug, Enbrel. Sandoz was seeking to launch a copycat called Erelzi.

Amgen Breaks Out After Beating Novartis In Blockbuster Patent Battle

Anthem

Bristol-Myers

Guardant Health Inc

Iovance Biotherapeutics

IQVIA Hlds

Medtronic

Veeva Systems

West Pharmaceutical Services

Acceleron Pharma

The pandemic has put the health care industry under a global spotlight.

10 Stocks to Invest in the Health Care Revolution

Its payouts have doubled in just five years.

Is Amgen a Great Dividend Stock?

AbbVie

AstraZeneca

Eli Lilly

Novartis

Pfizer

The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade.

Canada federal court dismisses drugmakers' plea challenging drug price rules

Amgen Inc. stock has rallied 26% over recent weeks (vs. about a 40% gain in the S&P 500) to its current level of $236 after falling to a low of $186 in late March as a rapid increase in the number of Covid-19 cases outside China resulted in heightened fears of an imminent global economic downturn.

Can Amgen See Higher Levels?

Amgen Inc. (AMGN) Presents at BMO 2020 Prescriptions for Success Healthcare Brokers Conference (Transcript)

Amgen Inc. (AMGN) Presents at BMO 2020 Prescriptions for Success Healthcare Conference (Transcript)

THOUSAND OAKS, Calif., June 22, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced it is supporting the further study of AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor, for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and...

Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries

THOUSAND OAKS, Calif., June 18, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference at 4:00 p.m. ET on Tuesday, June 23, 2020. Elliott Levy, senior vice president of R&D Strategy and Operations at Amgen,...

Amgen To Present At The BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

Amgen, Inc. (AMGN) Presents at Goldman Sachs Healthcare Conference (Transcript)

Amgen stock is consolidating as it takes a two-pronged approach to coronavirus treatment, partnering with Adaptive Biotechnologies and testing Otezla in Covid-19. Is Amgen stock a buy?

Is Amgen Stock A Buy As It Takes A Two-Pronged Approach To Coronavirus?

BioNTech SE

Gilead Sciences

GlaxoSmithKline

Several drugmakers have started ramping up production, anticipating huge demand if the candidates prove successful.

Drugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in Focus

THOUSAND OAKS, Calif., June 5, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 41st Annual Virtual Global Healthcare Conference on Wednesday, June 10, 2020 at 1:20 p.m. ET. Peter H. Griffith, executive vice president and chief financial officer, and David M....

Amgen To Present At The Goldman Sachs 41st Annual Global Healthcare Conference

NIKE

Target

With the coronavirus outbreak still weighing on companies, it's time to favor those with long-term drivers of revenue growth.

3 Top Large-Cap Stocks to Buy in June

Amgen Inc. (AMGN) Management Presents at Jefferies 2020 Virtual Healthcare Conference (Transcript)

Clinical trials of non-COVID-19 drugs have taken a backseat as most drugmakers and biotechnology companies are speeding up development of a vaccine for the novel coronavirus.

Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

News for Amgen Stock (AMGN)